ESLA (Estrella Immunopharma) 6-1 Month Momentum %: -36.49% (As of Aug. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ESLA Estrella Immunopharma Inc ESLA
12 GF Score
Price $0.71
! 1 Warning Sign
View Full Analysis

What is Estrella Immunopharma 6-1 Month Momentum %?

Estrella Immunopharma ESLA -1.11% 12 6-1 Month Momentum % is -36.49% as of Aug. 28, 2026. GuruFocus rates ESLA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,374 Biotechnology companies, Estrella Immunopharma ranks worse than 74.16% on this metric.

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-28), Estrella Immunopharma's 6-1 Month Momentum % is -36.49%.

The industry rank for Estrella Immunopharma's 6-1 Month Momentum % or its related term are showing as below:

ESLA's 6-1 Month Momentum % is ranked worse than
74.16% of 1374 companies
in the Biotechnology industry
Industry Median: -16.47 vs ESLA: -36.49

Estrella Immunopharma  (NAS:ESLA) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Estrella Immunopharma 6-1 Month Momentum % Related Terms

ESLA vs LITS, NNVC, LTRN: 6-1 Month Momentum % Comparison

For the Biotechnology subindustry, Estrella Immunopharma's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Estrella Immunopharma 6-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's 6-1 Month Momentum % falls into.


ESLA
12GF Score
Estrella Immunopharma Inc ESLA
6-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Estrella Immunopharma  (NAS:ESLA) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-1 Month Momentum % →
What does a 6-1 Month Momentum % of -36.49% mean?
Estrella Immunopharma (ESLA) has a 6-1 Month Momentum % of -36.49% as of Aug. 28, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Estrella Immunopharma and its competitors. According to the industry distribution chart, Estrella Immunopharma ranks #1019 out of 1374 companies in the Biotechnology industry, placing it in the top 74.2%.
Is Estrella Immunopharma's 6-1 Month Momentum % too high?
Estrella Immunopharma's current 6-1 Month Momentum % is -36.49%. Based on the distribution chart, Estrella Immunopharma ranks #1019 out of 1374 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Estrella Immunopharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Estrella Immunopharma's 6-1 Month Momentum % compare to LITS and NNVC?
According to the Biotechnology industry distribution chart, Estrella Immunopharma ranks #1019 out of 1374 companies for 6-1 Month Momentum %. This places Estrella Immunopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Estrella Immunopharma and its competitors. Estrella Immunopharma's current 6-1 Month Momentum % is -36.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Estrella Immunopharma stock overvalued right now?
Estrella Immunopharma (ESLA) has a current 6-1 Month Momentum % of -36.49%. The current 6-1 Month Momentum % is -36.49%. Estrella Immunopharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Estrella Immunopharma (ESLA), the current 6-1 Month Momentum % is -36.49% as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Estrella Immunopharma Business Description

Address 5858 Horton Street, Suite 370, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
12GF Score

Get the complete analysis for ESLA

6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price